Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Breast Radiation Score

To further improve outcomes and reduce unnecessary treatment for breast cancer patients, Exact Sciences is developing a genomic test designed to evaluate the activity of 16 cancer genes with the goal of determining benefit from radiation therapy after breast-conserving surgery. The gene expression signature developed by PFS Genomics, a company Exact Sciences acquired in early 2021, addresses a major clinical need: identifying which women with early-stage breast cancer need radiotherapy and which do not. Being able to provide women with a clear answer to this question has the potential to minimize over- or under-treatment and allow women to further personalize their breast cancer treatment plans.